Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-09-28

Reporting Person: Grossi Federico (CHIEF MEDICAL OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-28	Common Stock	M	4000	$3.76	Acquired	66930	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-28	Stock Option (Right to Buy)	$3.76	M	4000	Disposed	2026-02-06	Common Stock (4000)	Direct

Footnotes

F1: This option was granted on February 8, 2016 and is fully vested.